Gilead Sciences (GILD) Tops Q4 EPS by 17c; Guides
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $66.76 +0.91%
Revenue Growth %: -0.6%
Financial Fact:
Cost of goods sold: 1.13B
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: -0.6%
Financial Fact:
Cost of goods sold: 1.13B
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.67, $0.17 better than the analyst estimate of $1.50. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $6.66 billion.
GUIDANCE:
Gilead Sciences sees FY2023 EPS of $6.60-$7.00, versus the consensus of $6.73. Gilead Sciences sees FY2023 revenue of $26-26.5 billion, versus the consensus of $27 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss
- Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
- Parke Bancorp (PKBK) Reports Q1 EPS of $0.51
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
